Denali Therapeutics (NASDAQ:DNLI) Insider Alexander Schuth Sells 2,768 Shares of Stock

Denali Therapeutics Inc. (NASDAQ:DNLI) insider Alexander Schuth sold 2,768 shares of the firm’s stock in a transaction on Tuesday, September 1st. The shares were sold at an average price of $23.44, for a total value of $64,881.92. Following the completion of the sale, the insider owned 278,995 shares in the company, valued at $6,539,642.80. The trade was a 0.98% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Denali Therapeutics Stock Performance

Shares of DNLI opened at $22.80 on Friday. The firm has a fifty day moving average of $24.50 and a 200-day moving average of $21.83. The company has a market cap of $3.64 billion, a price-to-earnings ratio of -8.03 and a beta of 1.01. The company has a debt-to-equity ratio of 0.01, a quick ratio of 8.32 and a current ratio of 8.37. Denali Therapeutics Inc. has a 1 year low of $12.58 and a 1 year high of $27.30.

Denali Therapeutics (NASDAQ:DNLI) last released its quarterly earnings data on Thursday, August 6th. The company reported ($0.68) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.51) by ($0.17). The company had revenue of $3.60 million for the quarter, compared to analyst estimates of $2.15 million. During the same quarter in the previous year, the business posted ($0.72) earnings per share. As a group, equities analysts anticipate that Denali Therapeutics Inc. will post -2.67 earnings per share for the current year.

Hedge Funds Weigh In On Denali Therapeutics

Large investors have recently bought and sold shares of the stock. Mitsubishi UFJ Asset Management Co. Ltd. acquired a new stake in shares of Denali Therapeutics in the 2nd quarter worth approximately $26,000. Headlands Technologies LLC acquired a new position in shares of Denali Therapeutics during the second quarter valued at approximately $26,000. Global Retirement Partners LLC acquired a new position in shares of Denali Therapeutics during the second quarter valued at approximately $28,000. Johnson Financial Group Inc. acquired a new position in shares of Denali Therapeutics during the third quarter valued at approximately $29,000. Finally, State of Wyoming bought a new stake in Denali Therapeutics during the second quarter worth approximately $29,000. Institutional investors and hedge funds own 92.92% of the company’s stock.

Analyst Ratings Changes

A number of equities research analysts have recently weighed in on the company. Deutsche Bank Aktiengesellschaft lifted their price target on Denali Therapeutics from $31.00 to $35.00 and gave the company a “buy” rating in a report on Thursday, July 16th. Wall Street Zen raised Denali Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday, August 8th. UBS Group raised their target price on Denali Therapeutics from $25.00 to $34.00 and gave the company a “buy” rating in a research report on Friday, August 7th. B. Riley Financial lifted their target price on Denali Therapeutics from $30.00 to $35.00 and gave the company a “buy” rating in a research note on Tuesday, August 25th. Finally, Robert W. Baird set a $34.00 price target on Denali Therapeutics in a research report on Friday, August 7th. Fourteen equities research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $35.85.

About Denali Therapeutics

Denali Therapeutics is a clinical‐stage biopharmaceutical company focused on developing therapies for neurodegenerative diseases. The company’s research leverages a proprietary Blood–Brain Barrier Transport Vehicle (TV) platform designed to enable large molecules, including antibodies and enzymes, to penetrate the central nervous system. Denali’s approach includes small molecules, monoclonal antibodies and gene therapy candidates aimed at key drivers of disorders such as Alzheimer’s disease, Parkinson’s disease, amyotrophic lateral sclerosis (ALS) and frontotemporal dementia.

Among Denali’s lead programs is an orally delivered leucine‐rich repeat kinase 2 (LRRK2) inhibitor for Parkinson’s disease, and an anti‐TREM2 antibody designed to modulate microglial activity in Alzheimer’s patients.